1. CareDx announced awards of 113,250 shares to 49 new employees. 2. Dr. Jeffrey Teuteberg received 88,180 RSUs as Chief Medical Officer. 3. RSUs will vest over four years, incentivizing employee retention. 4. Awards follow Nasdaq regulations, supporting corporate governance compliance. 5. Investment in talent may enhance operational effectiveness in transplant solutions.
The inducement grants reflect CDNA's commitment to talent, which can drive growth. Previous examples show that attracting key personnel can positively influence market perceptions and stock performance.
The awards are a strategic move to strengthen CareDx’s workforce, likely improving future operational efficiency and market performance.
Investments in human capital through RSUs often provide long-term benefits, enhancing company innovation and growth trajectory over time.
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants.
On November 4, 2025, as an inducement material to acceptance of employment with CareDx, 49 new employees were awarded restricted stock units (RSUs) for an aggregate of 113,250 shares of common stock.
Additionally, on November 4, 2025, CareDx granted to Dr. Jeffrey Teuteberg, the Company's newly appointed Chief Medical Officer, 88,180 RSUs as an inducement material to Dr. Teuteberg's acceptance of employment with CareDx.
The RSU awards were made pursuant to the Company's 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniversary of each employee's vesting commencement date, and 1/16th of the RSUs vesting on each date that is three (3) months thereafter subject to each employee's continued service through each vesting date.
CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
View source version on businesswire.com: https://www.businesswire.com/news/home/20251107124581/en/
CareDx
Media
Natasha Moshirian Wagner
nwagner@caredx.com
Investor Relations
Caroline Corner
investor@caredx.com